LLY

AI Memo

Eli Lilly and

As of 2026-10-11/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-11 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

October 29 Q3 results test incretin volume and raised guidance • 2026-10-29

Base target: $1260 / p=50% prob

Biggest risk

At a premium multiple, weaker net pricing, margin dilution, safety or regulatory setbacks, or a Q3 guidance disappointment could outweigh strong unit demand. Acquired IPR&D charges already reduced the Q2 full-year non-GAAP EPS bridge. [#SEC-8K-2026-08-05]

Invalidation

Break below $970 or thesis failure.

What would change my mind?

The $85–87 billion 2026 revenue outlook and Q2 volume growth support further earnings expansion if incretin uptake and manufacturing capacity scale, while retatrutide and EloraTZP extend pipeline duration. [#SEC-8K-2026-08-05]

Research note

Recommendation

—

Confidence

medium

As of

2026-10-11

Base target

$1260

p=50%

Bull target

$1440

p=30%

Bear target

$970

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

EloraTZP Phase 3 initiation by year-end
The $85–87 billion 2026 revenue outlook and Q2 volume growth support further earnings expansion if incretin uptake and manufacturing capacity scale, while retatrutide and EloraTZP extend pipeline duration.
[#SEC-8K-2026-08-05]

BearKey bullets

EloraTZP Phase 2b tolerability and discontinuations may complicate Phase 3 execution.
[#PR-2026-09-30]
Lilly's 2025 filing says most products were sold to wholesalers and names McKesson, Cencora and Cardinal Health as significant U.S.

WatchKey bullets

October 29 Q3 results test incretin volume and raised guidance

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $1260 (p=50%)

Target spread vs base: +14% / -23%

Scenario probabilities

Bull Target: $1440 (p=30%)Base Target: $1260 (p=50%)Bear Target: $970 (p=20%)

Commentary

Primary operating evidence remains positive, but the recent-news packet is sparse and largely unrelated to Lilly. No verified post-event price reaction, recent target revision, options skew, short-interest reading or sufficient social coverage is available; zero sentiment inputs mean unavailable, not neutral measurements. The lower driver-density prior (0.6 versus 1.0 previously) warrants a measured, Q3-dependent view rather than a stronger upgrade.

As of 2026-10-11 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

EloraTZP Phase 3 initiation by year-end

Scenarios

Bull Target (Scenario probability)

$1440 / p=30% prob

Base Target (Scenario probability)

$1260 / p=50% prob

Bear Target (Scenario probability)

$970 / p=20% prob

Analysis 2026-10-11 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-29
October 29 Q3 results test incretin volume and raised guidance
Lilly scheduled its Q3 call for October 29. Q2 revenue rose 48% to $23.0 billion, chiefly on Mounjaro and Zepbound volume, and Lilly raised 2026 revenue guidance to $85–87 billion. Q3 volume, realized pricing, margins and the guidance bridge are the decision points; no Q3 result is yet available. [#SEC-8K-2026-08-05] [#8-K-2026-08-05] [#IR-2026-10-29] Lilly event page
Prob 85.00% • Move 4.00% • Priced-in 75.00%
EVENT2027-03-31
Retatrutide U.S. obesity submission planned for Q1 2027
Lilly says its Phase 3 package supports a planned FDA biologics-license submission in Q1 2027. Its September TRIUMPH-2 release reported 20.8% mean weight loss at 80 weeks for the 12 mg group with obesity and type 2 diabetes. Filing timing, safety review and approval remain uncertain. [#SEC-8K-2026-08-05] [#PR-2026-09-29] Lilly trial release
Prob 78.00% • Move 5.00% • Priced-in 70.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

EloraTZP Phase 3 initiation by year-end
2026-12-31
Lilly plans to initiate Phase 3 studies of its eloralintide–tirzepatide co-formulation by the end of 2026 after Phase 2b results. Initiation would broaden its obesity pipeline, not validate Phase 3 efficacy; the precise start date is unannounced. [#PR-2026-09-30] Lilly release
Prob 72% • Move 2% • Priced-in 55%

Risks

EloraTZP Phase 2b tolerability and discontinuations may complicate Phase 3 execution. [#PR-2026-09-30]
Lilly's 2025 filing says most products were sold to wholesalers and names McKesson, Cencora and Cardinal Health as significant U.S. distributors; customer-specific exposure and any current disruption are unknown. [#REL-cabf7e76-a390-43fd-8da6-8842bff320e0] [#REL-213e20b8-6e52-4900-8c16-31eed0422e11] [#REL-f82afacc-d048-4280-95b5-168e05ef869b] [#REL-0b353a22-b421-4ee0-9cd6-aa4dafe54cc2] 2025 10-K
Retatrutide remains investigational; filing, safety review and eventual approval are uncertain. [#PR-2026-09-29]
The Q3 result could expose weaker realized incretin pricing, slower volume growth, or margin pressure relative to raised 2026 revenue guidance. [#SEC-8K-2026-08-05]

Peers

Symbol	Summary
AMGN	Large-cap biopharma comparator with obesity-pipeline optionality, but much less established incretin revenue than Lilly.
MRK	Commercial-scale branded-pharma comparator; pipeline durability is comparable, obesity exposure is not.
AZN	Diversified branded-pharma and oncology comparator; useful for pipeline breadth, not a direct obesity-demand comp.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-11

Loading AI feed…

Symbol

Summary

AMGN

Large-cap biopharma comparator with obesity-pipeline optionality, but much less established incretin revenue than Lilly.

MRK

Commercial-scale branded-pharma comparator; pipeline durability is comparable, obesity exposure is not.

AZN

Diversified branded-pharma and oncology comparator; useful for pipeline breadth, not a direct obesity-demand comp.